Balancing benefits and harms of treatments for acute bipolar depression
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bipolar depression is more pervasive than mania, but has fewer evidence-based treatments. METHODS: Using data from multicenter, randomized, double-blind, placebo-controlled trials and meta-analyses, we assessed the number needed to treat (NNT) for response and the number needed to harm (NNH) for selected side effects for older and newer acute bipolar depression treatments. RESULTS: The 2 older FDA-approved treatments for bipolar depression, olanzapine-fluoxetine combination (OFC) and quetiapine (QTP) monotherapy, were efficacious (response NNT=4 for OFC, NNT=6 for QTP), but similarly likely to yield harms (OFC weight gain NNH=6; QTP sedation/somnolence NNH=5). Commonly used unapproved agents (lamotrigine monotherapy and adjunctive antidepressants) tended to be well-tolerated (with double-digit NNHs), although this advantage was at the cost of inadequate efficacy (response NNT=12 for lamotrigine, NNT=29 for antidepressants). In contrast, the newly approved agent lurasidone was not only efficacious (response NNT=5 for monotherapy, NNT=7 as adjunctive therapy), but also had enhanced tolerability (NNH=15 for akathisia [monotherapy], NNH=16 for nausea [adjunctive]). Although adjunctive armodafinil appeared well tolerated, its efficacy in bipolar depression has not been consistently demonstrated in randomized controlled trials. LIMITATIONS: NNT and NNH are categorical metrics; only selected NNHs were assessed; limited generalizability of efficacy (versus effectiveness) studies. CONCLUSION: For acute bipolar depression, older approved treatments may have utility in high-urgency situations, whereas lamotrigine and antidepressants may have utility in low-urgency situations. Newly approved lurasidone may ultimately prove useful in diverse situations. New drug development needs to focus on not only efficacy but also on tolerability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681 · cited 4×
“NNT, the expected number of subjects who would need to be treated to yield 1 additional good outcome, compared with a control intervention (Citrome, 2008; Citrome, 2009b; Laupacis et al., 1988), was calculated for response in acute bipolar depression (i.”
BackgroundResultInfluentialJudd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243 · cited 2×
“Depressive compared with manic states are more pervasive (Judd et al., 2003; Judd et al., 2002) and, thus, crucially contribute to functional impairment (Altshuler et al.”
BackgroundExcess Mortality in Bipolar and Unipolar Disorder in Sweden
Ösby, U., Brandt, L., Correia, N., Ekbom, A., & Sparén, P. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.9.844 · Cited by 1,120 · cited 2×
“, 2008), many succumb to premature cardiovascular, cerebrovascular, gastrointestinal, or other medical causes of mortality (Osby et al., 2001).”
BackgroundEffectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064135 · Cited by 937 · cited 2×
“, 2003) and another contributed approximately 32% of the patients (Sachs et al., 2007), so that the remaining 4 studies accounted for only approximately 26% of all patients (Amsterdam and Shults, 2005; Cohn et al.”
BackgroundSelf-citationTohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationCalabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 3×
“In 2006, quetiapine monotherapy received FDA approval for acute bipolar depression, not only in patients with bipolar I disorder, but also in patients with bipolar II disorder (Calabrese et al., 2005; Thase et al., 2006).”
BackgroundResultSelf-citationJudd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Leon, A. C., Solomon, D. A., Coryell, W., Maser, J. D., & Keller, M. B. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.12.1322 · Cited by 577 · cited 2×
“, 2002) and, thus, crucially contribute to functional impairment (Altshuler et al., 2002; Judd et al., 2005).”
BackgroundThase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559 · cited 2×
“In 2006, quetiapine monotherapy received FDA approval for acute bipolar depression, not only in patients with bipolar I disorder, but also in patients with bipolar II disorder (Calabrese et al., 2005; Thase et al., 2006).”
BackgroundResultSelf-citation
Cited by
Ashok, A. H., Marques, T. R., Jauhar, S., Nour, M. M., Goodwin, G. M., Young, A. H., & Howes, O. D. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.16 · Cited by 546
Grunebaum, M. F., Ellis, S. P., Keilp, J. G., Moitra, V. K., Cooper, T. B., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., et al. (2017) · Bipolar Disorders · doi:10.1111/bdi.12487 · Cited by 174
Morton, E., Sakai, K., Ashtari, A., Pleet, M., Michalak, E. E., & Woolley, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221131997 · Cited by 78
Kato, T., Ishigooka, J., Miyajima, M., Watabe, K., Fujimori, T., Masuda, T., Higuchi, T., & Vieta, E. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13137 · Cited by 49
“Many antipsychotics have demonstrated efficacy in treatment of acute manic and mixed manic episodes; however, randomized trials of lurasidone have not been reported.(40) The results of the current study found lurasidone to have minimal effects on weight and metabolic parameters.”
BackgroundGosmann, N. P., Costa, M. D. A., Jaeger, M. D. B., Frozi, J., Spanemberg, L., Manfro, G. G., Cortese, S., Cuijpers, P., Pine, D. S., & Salum, G. A. (2023) · Psychological Medicine · doi:10.1017/s0033291723001630 · Cited by 28
“All included SSRIs and SNRIs have shown incidence rates of adverse events comparable to benzodiazepines and antipsychotics, drug classes that present some evidence supporting their efficacy of these medications for anxiety symptoms (Arbanas, Arbanas, & Dujam, 2009; Ketter et al., 2014).”
Background
Metadata
- Authors
- Ketter, T. A., Miller, S., Dell'Osso, B., Calabrese, J. R., Frye, M. A., & Citrome, L.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 169
- Pages
- S24-S33
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W2070454612
- Cited by
- 47
- References
- 15
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Balancing benefits and harms of treatments for acute bipolar depression. https://app.cochat.ai/papers/10.1016/s0165-0327(14)70006-0
- The paper
- Ketter, T. A., Miller, S., Dell'Osso, B., Calabrese, J. R., Frye, M. A., & Citrome, L. (2014). Balancing benefits and harms of treatments for acute bipolar depression. Journal of Affective Disorders. https://doi.org/10.1016/s0165-0327(14)70006-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.